
## ASO VISUAL ABSTRACT

## ASO Visual Abstract: Evaluating Axillary Lymph Node Yield After Neoadjuvant Chemotherapy

Betty Fan, DO<sup>1</sup>, Kelsey Romatoski, MD<sup>2</sup>, Jaime Pardo, MD<sup>2</sup>, Monica Valero, MD<sup>2</sup>, Stephanie Serres, MD<sup>2</sup>, Rene Flores, MD<sup>2</sup>, and Ted James, MD, MHCM, FACS<sup>2</sup>

<sup>1</sup>Breast Surgery, Department of Surgical Oncology, Indiana University School of Medicine, Indiana University Health, Indianapolis; <sup>2</sup>Breast Surgical Oncology, Department of Surgery, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA



Lymph node yield did not differ after an axillary lymph node dissection between the patients who received neoadjuvant chemotherapy and those who did not (https://doi.org/10.1245/s10434-022-12438-8).

**FUNDING** No funding was obtained for this project. Dr. Ted James—Advisor: Perimeter Medical.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.